NCT04971109Phase 3Completed

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-05-12Actual

Enrollment · participants467Actual

Source updated2026-09-11Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Smallpox

Treatments or interventions studied

TPOXXDrugAlso known as tecovirimat

Primary outcomes · main study measures

Read the study measures

measure: Cmin; description: Cmin - Minimum TPOXX concentration in plasma; timeFrame: 28 days; measure: Cmax; description: Peak exposure when administered TPOXX; timeFrame: 28 days; measure: AUC(0-last) - Total Systemic TPOXX Exposure; description: Total systematic exposure when administered TPOXX; timeFrame: 28 days; measure: Time To Maximum TPOXX Exposure; description: Median hours post dose when administered TPOXX; timeFrame: 28 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history